News | March 31, 2007

Cordis Begins Trial for New Vascular Closure Device

April 2, 2007 — Cordis Corp. has announced today the start of the pivotal trial for the ExoSeal Vascular Closure Device. The ECLIPSE Trial is a multicenter, non-blinded, randomized study designed to measure the safety and efficacy of the ExoSeal Vascular Closure Device versus manual compression to close vascular access sites in patients having undergone diagnostic or interventional procedures.

The trial will encompass 400 patients from 18 medical centers across the U.S.

On February 13, Principal Investigator Chiu Wong, M.D., associate professor of Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center and a Cordis Corp. Consultant, treated the first patient in the trial. Prior to the start of the ECLIPSE Trial, the ExoSeal(TM) Vascular Closure Device had been used in 150 patients participating in a first-in-human study for the device.

"The results from the first-in-man study were very encouraging, and this trial will help us determine whether those results can be maintained in a larger number of patients," said Dr. Wong. "As an interventional cardiologist, I welcome the opportunity to investigate a device that could help patients recover faster from a catheterization procedure."

The ExoSeal Vascular Closure Device features a synthetic bioabsorbable polymer and is being studied to determine whether it can enable expedited hemostasis (the cessation of bleeding), faster patient ambulation (ability to walk) and reduced bed-stay after a catheterization procedure. It also represents Cordis' entry into the vascular closure device market. Nearly eight million patients undergo cardiac catheterization procedures annually.

For more information visit www.cordis.com.

Related Content

Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Vivasure Medical, Closure Device, Series C financing
News | Vascular Closure Devices| September 12, 2016
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.
Rex medical, Closer Vascular Sealing System, VSS, vascular closure, bioresorbable vascular closure device

A close up view of the Rex Medical Closer Vascular Sealing System components.

Technology | Vascular Closure Devices| August 03, 2016
August 3, 2016 — The U.S.
Vivasure Medical, PerQSeal, vascular closure device, CE Mark
News | Vascular Closure Devices| January 18, 2016
Vivasure Medical announced Conformité Européenne (CE) Mark approval of the world’s first fully bioabsorbable...
News | Vascular Closure Devices| December 16, 2015
Scientists at CBSET have presented preclinical evidence that the Manta Large Bore Vascular Closure Device (VCD) from...
Technology | November 06, 2014
Cardinal Health announced that its MynxGrip Vascular Closure Device recently received U.S. Food and Drug Administration...
Videos | Vascular Closure Devices| September 26, 2014
Doug Drachman, M.D., Mass General Hospital Institute of Heart, Vascular and Stroke Care, explains how to prevent and
Feature | September 17, 2014
September 17, 2014 — A new clinical trial found that vascular closure devices (VCDs) are non-inferior to manual...
Cardiva Medical Inc. Vascade Vascular Closure System Series 3 financing U.S.
News | August 21, 2014
Cardiva Medical Inc. said it closed the first two tranches of a $16.5 million Series 3 private equity financing and a $...
Overlay Init